JP2024519188A5 - - Google Patents

Info

Publication number
JP2024519188A5
JP2024519188A5 JP2024515728A JP2024515728A JP2024519188A5 JP 2024519188 A5 JP2024519188 A5 JP 2024519188A5 JP 2024515728 A JP2024515728 A JP 2024515728A JP 2024515728 A JP2024515728 A JP 2024515728A JP 2024519188 A5 JP2024519188 A5 JP 2024519188A5
Authority
JP
Japan
Prior art keywords
group
groups
cancer
general formula
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/094612 external-priority patent/WO2022247816A1/zh
Publication of JP2024519188A publication Critical patent/JP2024519188A/ja
Publication of JP2024519188A5 publication Critical patent/JP2024519188A5/ja
Pending legal-status Critical Current

Links

JP2024515728A 2021-05-24 2022-05-24 含窒素複素環系化合物、その調製方法及びその医薬的応用 Pending JP2024519188A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202110565410 2021-05-24
CN202110565410.0 2021-05-24
CN202110694022 2021-06-22
CN202110694022.2 2021-06-22
CN202110856289.7 2021-07-28
CN202110856289 2021-07-28
CN202210198679.4 2022-03-02
CN202210198679 2022-03-02
PCT/CN2022/094612 WO2022247816A1 (zh) 2021-05-24 2022-05-24 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
JP2024519188A JP2024519188A (ja) 2024-05-08
JP2024519188A5 true JP2024519188A5 (cg-RX-API-DMAC7.html) 2025-06-03

Family

ID=84229501

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515728A Pending JP2024519188A (ja) 2021-05-24 2022-05-24 含窒素複素環系化合物、その調製方法及びその医薬的応用

Country Status (11)

Country Link
US (1) US20240287094A1 (cg-RX-API-DMAC7.html)
EP (1) EP4349836A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024519188A (cg-RX-API-DMAC7.html)
KR (1) KR20240012437A (cg-RX-API-DMAC7.html)
CN (1) CN117177971A (cg-RX-API-DMAC7.html)
AU (1) AU2022280845A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022496A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219858A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013890A (cg-RX-API-DMAC7.html)
TW (1) TWI926045B (cg-RX-API-DMAC7.html)
WO (1) WO2022247816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
KR20250103773A (ko) * 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors
JP2026524090A (ja) 2023-06-08 2026-07-17 上海森▲輝▼医▲葯▼有限公司 ホルムアミド系化合物の製造方法
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) * 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parpおよびtank阻害剤としてのキノリノン誘導体
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
WO2020098774A1 (zh) * 2018-11-16 2020-05-22 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
CN116018132A (zh) 2020-06-24 2023-04-25 Itf研究制药有限公司 软明胶胶囊
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1

Similar Documents

Publication Publication Date Title
CN111295384A (zh) 双环类衍生物抑制剂、其制备方法和应用
JP2024522766A5 (cg-RX-API-DMAC7.html)
US11878000B2 (en) Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2019535720A5 (cg-RX-API-DMAC7.html)
JP2014503574A5 (cg-RX-API-DMAC7.html)
RU2020102453A (ru) Фармацевтические композиции
JP2019529444A5 (cg-RX-API-DMAC7.html)
IL319292A (en) Cytotoxic imidazo[2,1-A]pyridine compounds and their use in therapy
JP2023530456A5 (cg-RX-API-DMAC7.html)
JP2019509986A (ja) トリプトライドのグルコース・コンジュゲート、その類縁体及び使用
US20250154098A1 (en) Substituted bisphenylalkylurea compounds and methods of treating breast cancer
JP2020503376A5 (cg-RX-API-DMAC7.html)
JP2017503753A5 (cg-RX-API-DMAC7.html)
EP2144887A1 (en) Dosages and methods for the treatment of cancer
JP2025111532A (ja) 5-ブロモピリジン-3-イル-3-デオキシ-3-[4-(3,4,5-トリフルオロフェニル)-1h-1,2,3-トリアゾール-1-yl]-1-チオ-アルファ-d-ガラクトピラノシド及びその結晶形を調製するための大規模方法
EP4591940A3 (en) Deoxy- cytidine derivatives for use in cancer therapies
JP2005531563A5 (cg-RX-API-DMAC7.html)
JP2018140987A5 (cg-RX-API-DMAC7.html)
US20160102066A1 (en) Benzothiazole derivative and anti-tumor use thereof
US20160102095A1 (en) Pyrazolo[1,5-a]pyrimidine derivative and use of anti-tumor thereof
KR102138415B1 (ko) 신규 peg 유도체
JP4267447B2 (ja) 細胞増殖抑制作用を有するランタン化合物
US20240140947A1 (en) Compound for the treatment of cancer
Geleverya et al. Synthesis of new 4, 4’-(1H-1, 2, 3-triazole)-bis (1H-pyrazol-5-ols) and prospects for their study as potential antitumor agent